NCT02603679View on ClinicalTrials.gov

Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 30, 2021

Study Completion Date

December 31, 2031

Conditions
Early-Stage Breast CarcinomaEstrogen Receptor Positive Tumor
Interventions
DRUG

Paclitaxel

Any brand of paclitaxel may be used, excluding nab-paclitaxel

DRUG

Tamoxifen + Palbociclib

Any brand of tamoxifen may be used

DRUG

Aromatase Inhibitor + Palbociclib

Any brand of letrozole, anastrozole or exemestane may be used

DRUG

Goserelin + Aromatase Inhibitor + Palbociclib

Any brand of letrozole, anastrozole or exemestane may be used

Trial Locations (3)

11883

Södersjukhuset, Stockholm

17176

Karolinska University Hospital, Stockholm

Unknown

Capio S:t Göran Hospital, Stockholm

All Listed Sponsors
lead

Thomas Hatschek

OTHER

NCT02603679 - Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases | Biotech Hunter | Biotech Hunter